← Leaderboards
Aleksandar None Sekulic
Mayo Clinic Arizona
$3,213,996
Attributed
$3,213,996
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $750.6K · FY2014–18$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,213,996 · 2
By mechanism
R01$3,213,996 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelInnovationMolecularTissuesCellsBaseMalignant NeoplasmsMelanomaTumorBraf GenePlayPathway InteractionsResearch StudyCell Death ProcessCarcinogenesisBasal Cell CarcinomaCancer CellArchivesAffectClinically RelevantClinicBiologyAntineoplastic AgentsCessation Of Life
Grant awards (9)
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma$346,236
R01 · FY2018 · CA · contact PI
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma$348,312
R01 · FY2017 · CA · contact PI
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma$346,236
R01 · FY2017 · CA · contact PI
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma$352,036
R01 · FY2016 · CA · contact PI
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma$351,883
R01 · FY2016 · CA · contact PI
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma$366,691
R01 · FY2015 · CA · contact PI
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma$352,036
R01 · FY2015 · CA · contact PI
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma$382,030
R01 · FY2014 · CA · contact PI
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma$368,536
R01 · FY2014 · CA · contact PI